NCT07180186View on ClinicalTrials.gov

Microbiota and Probiotic Therapy in Ulcerative Colitis Patients

CompletedOBSERVATIONAL
Enrollment

70

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

May 1, 2024

Study Completion Date

May 1, 2024

Conditions
MicrobiotaProbiotic TherapyUlcerative Colitis
Interventions
DRUG

Mesalamine

Patients with ulcerative colitis in remission treated with oral mesalamine.

DRUG

Probiotics (Bacillus Clausii)

Patients with ulcerative colitis in remission treated with probiotics (Bacillus Clausii).

DRUG

Mesalamine and probiotics (Bacillus Clausii)

Patients with ulcerative colitis in remission treated with oral mesalamine and probiotics (Bacillus Clausii).

Trial Locations (1)

31527

Tanta University, Tanta

All Listed Sponsors
lead

Tanta University

OTHER

NCT07180186 - Microbiota and Probiotic Therapy in Ulcerative Colitis Patients | Biotech Hunter | Biotech Hunter